Home > Boards > US Listed > Biotechs >

Idera Pharmaceuticals, Inc. (IDRA)

IDRA RSS Feed
Add IDRA Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator noretreat, TOB, Seel
Search This Board:
Last Post: 7/22/2014 2:42:47 PM - Followers: 111 - Board type: Free - Posts Today: 0



The Company has created DNA-based compounds that in preclinical studies act as antagonists of TLR7 and TLR9, such as IMO-3100, or as antagonists of TLRs 7, 8, and 9, such as IMO-8400. The Company is developing IMO-3100, an antagonist of TLR7 and TLR9, for the treatment of psoriasis. It has selected IMO-8400, an antagonist of TLRs 7, 8, and 9, for development in the treatment of autoimmune diseases, with lupus as the initial disease indication. IMO-2055, a TLR9 agonist, is its lead drug candidate for the treatment of cancer. Clinical trials of IMO-2055 completed by the Company or by Merck KGaA include four Phase I clinical trials, of which two were in healthy subjects and two were in refractory cancer patients, and one Phase II clinical trial. The Phase II clinical trial was a monotherapy trial of IMO-2055 in patients with metastatic or recurrent clear cell renal cancer.


In preclinical animal models, the Company TLR7, 8, and 9 agonists have shown adjuvant activity when combined with various types of antigens. It has designed and created a new class of molecules to inhibit gene expression. These gene silencing oligonucleotides, which it refer to as GSOs, are nucleic acid-based and represent a novel approach to selectively, silence gene expression. It is actively engaged in preclinical research with its GSOs that is designed to explore their potential as research reagents and therapeutic agents. In addition to the Company’s clinical programs in autoimmune and inflammatory diseases and in cancer, it has identified TLR drug candidates for applications in the treatment of infectious diseases, respiratory diseases and hematological malignancies, and TLR3 agonists for use as vaccine adjuvants.


IMO-2125, a synthetic DNA-based TLR9 agonist, is its lead candidate for the treatment of chronic hepatitis C virus (HCV), infection. The Company conducted two Phase I clinical trials of IMO-2125 in patients with chronic HCV infection, one in patients with HCV who had not responded to prior treatment and one in combination with ribavirin, an antiviral medication approved for use in combination with interferon-alpha in the treatment of HCV infection, in treatment-naive patients with genotype 1 chronic HCV infection. In addition to the use of TLR9 agonists in oncology applications, it selected IMO-4200 as a lead TLR7 and TLR8 agonist candidate for the treatment of hematological cancers. Its TLR9 agonists are designed to induce immune responses that could be useful in restoring immune system balance. IMO-2134 is its lead TLR9 agonist for asthma and allergies. In addition to use of TLR7, 8, and 9 agonists as vaccine adjuvants, it also has created TLR3 agonists for potential use as vaccine adjuvants.


The Company competes with Dynavax Technologies Corporation, GlaxoSmithKline plc., Pfizer, Inc., VentiRx Pharmaceuticals., Novartis, Dynavax Technologies Corporation, VaxInnate, Inc., Intercell AG, Cytos Biotechnology AG and Celldex Therapeutics, Inc.

http://www.iderapharma.com/

 


 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IDRA
Current Price
Volume:
Bid Ask Day's Range
Wiki
Option Chain for IDRA
IDRA News: Statement of Changes in Beneficial Ownership (4) 07/03/2014 04:44:35 PM
IDRA News: Statement of Changes in Beneficial Ownership (4) 07/03/2014 04:26:10 PM
IDRA News: Statement of Changes in Beneficial Ownership (4) 07/03/2014 02:32:37 PM
IDRA News: Idera Pharmaceuticals to Participate in a Panel Discussion at the Piper Jaffray GenomeRx Symposium 06/17/2014 08:00:00 AM
IDRA News: Idera Pharmaceuticals to Present at the Nucleic Acid Summit 2014 06/13/2014 04:25:00 PM
PostSubject
#718  Sticky Note Hi Seel. Let me assure you that despite ajsmith 03/09/14 01:35:35 AM
#1305   Been lurking for a while but finally bought Beandog 07/22/14 02:42:47 PM
#1304   Add strikingly cool mgmt and science, you have binchey 07/22/14 11:29:57 AM
#1303   Quietly loaded with IDRA here as well. TOB 07/22/14 11:07:13 AM
#1302   My situation as well. I am loaded and Markmark1 07/22/14 07:33:28 AM
#1301   Going to need to dip below $2.50 again Randolph Duke 07/21/14 08:57:26 PM
#1300   Got some at the close for 2.66 Black sunshine 07/21/14 07:09:48 PM
#1299   Wish I had something useful to offer. I'm Seel 07/21/14 07:09:27 PM
#1298   Kinda quiet lately......anybody buying still, or waiting? THEPK5 07/21/14 03:31:37 PM
#1297   Thanks PK5. Citrati 07/17/14 11:10:07 PM
#1296   Good call. THEPK5 07/16/14 11:58:53 AM
#1295   market valuations now? After years of printing $$$. Randolph Duke 07/15/14 12:32:44 PM
#1294   I'm thinking she should have kept her opinions THEPK5 07/15/14 12:21:39 PM
#1293   New update from the FED steppe 07/15/14 11:35:26 AM
#1292   Why the beat down in bios today? THEPK5 07/15/14 11:26:43 AM
#1291   Still thinking the same? THEPK5 07/14/14 07:34:48 PM
#1290   Idera Pharmaceuticals, Inc. [$IDRA] due diligence stocktrademan 07/12/14 12:52:28 PM
#1289   Reborn? Lol. GLTA. Markmark1 07/08/14 10:25:27 PM
#1288   Same here....I guess that's pretty obvious. A THEPK5 07/08/14 07:55:48 PM
#1287   Added to my position too. Would like to Markmark1 07/08/14 01:40:21 PM
#1286   Added 15,000 IDRAs today, I could not resist! binchey 07/08/14 01:06:35 PM
#1285   Hope not. Got a TON at $2.79 Black sunshine 07/07/14 06:14:49 PM
#1284   was almost a BUY then it broke under Randolph Duke 07/07/14 05:53:12 PM
#1283   No, not yet. Here is why. Citrati 07/07/14 03:26:23 PM
#1282   Anybody buying today? THEPK5 07/07/14 01:41:54 PM
#1281   All 3 Form 4's reported Director's Compensation taken CHM_760 07/04/14 08:42:43 AM
#1280   Here is a listing of all the "insider" Citrati 07/03/14 06:36:47 PM
#1279   Form out: more insider buying by the baker bros? steppe 07/03/14 03:26:58 PM
#1278   Link? THEPK5 07/03/14 09:59:14 AM
#1277   Nice post but I see that it was moneycents 07/02/14 10:09:25 PM
#1276   Looks like the sec could be looking at 1vman 07/02/14 06:54:15 PM
#1275   Til it heads south..... THEPK5 07/02/14 11:48:27 AM
#1274   Had 9k shares back at 2.45. Wish Black sunshine 07/01/14 09:26:12 PM
#1273   Its been couple weeks since I got up SiriSkiBum 07/01/14 08:19:20 PM
#1272   Going to load up more myself if it Black sunshine 07/01/14 08:11:42 PM
#1271   I never blow my load in one go. SiriSkiBum 07/01/14 07:50:21 PM
#1270   Same here. Down today, thought $2.88 was Black sunshine 07/01/14 05:17:59 PM
#1269   you're not alone. I had a BID sitting Randolph Duke 07/01/14 03:59:58 PM
#1268   What's with the giant bid/ask right now? THEPK5 07/01/14 02:29:38 PM
#1267   Thanks, interesting and yes, I would guess there tutankhamen 07/01/14 07:18:11 AM
#1266   There are lots of ways that entities that nsomniyak 07/01/14 12:34:06 AM
#1265   You would think...xx$i a tobacco company also got tutankhamen 06/30/14 01:39:33 PM
#1263   one would think so... except for this thing macnqueso 06/30/14 08:16:59 AM
#1262   All of these big volumes you have been nsomniyak 06/30/14 01:33:45 AM
#1261   4.5 M shares AH RealGenius 06/29/14 04:47:13 PM
#1260   LOL, speak of the devil (answer man) from Citrati 06/28/14 01:50:54 AM
#1259   Index funds buy at the close - they nsomniyak 06/27/14 10:48:13 PM
#1258   But wouldn't addition to index pushed it up? THEPK5 06/27/14 10:20:07 PM
#1257   Yes, IDRA also added to the Russell today CHM_760 06/27/14 08:06:30 PM
#1256   Could be due to addition to Russell 3000 Citrati 06/27/14 07:23:24 PM
#1255   What's with the major volume today? THEPK5 06/27/14 06:01:14 PM
PostSubject